4-chloro-6-methoxy-2,3-dihydrofuro<3,2-c>quinoline | 140633-18-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-chloro-6-methoxy-2,3-dihydrofuro<3,2-c>quinoline
• 英文别名: 4-chloro-6-methoxy-2,3-dihydro-furo[3,2-c]quinoline；4-Chlor-6-methoxy-2,3-dihydro-furo[3,2-c]chinolin；4-Chloro-6-methoxy-2,3-dihydrofuro[3,2-c]quinoline
• CAS: 140633-18-7
• 化学式: C₁₂H₁₀ClNO₂
• 分子量: 235.67
• InChiKey: RAIHNJPXCGBXTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-methoxy-3,5-dihydro-2H-furo[3,2-c]quinolin-4-one 在 三氯氧磷 作用下， 生成 4-chloro-6-methoxy-2,3-dihydrofuro<3,2-c>quinoline 、 2,4-dichloro-3-(2-chloroethyl)-8-methoxyquinoline
  参考文献：
  名称：

  417.烟酰胺和γ-牛磺酸的合成

  摘要：

  DOI：

  10.1039/jr9570002177

文献信息

• Dihydropyrrolo quinoline derivatives
  申请人：SmithKline Beckman Intercredit B.V.

  公开号：US05051508A1

  公开（公告）日：1991-09-24

  1,4-Substituted 2,3-dihydropyrrolo[3,2-c]quinolines which are inhibitors of H.sup.+ K.sup.+ ATPase activity and useful as inhibitors of gastric acid secretion. A compound of the invention is 1-(2-methylphenyl)-4-amino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline.

  1,4-取代的2,3-二氢吡咯并[3,2-c]喹啉是H.sup.+ K.sup.+ ATP酶活性的抑制剂，也可作为胃酸分泌抑制剂使用。该发明的化合物是1-(2-甲基苯基)-4-氨基-6-甲基-2,3-二氢吡咯并[3,2-c]喹啉。
• Quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：SMITHKLINE BEECHAM INTERCREDIT B.V.

  公开号：EP0307078A1

  公开（公告）日：1989-03-15

  in which R¹ to R⁴ are the same or different and are inter alia, each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, R¹⁰ is inter alia hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂)nOH in which n is 0 to 4 or amino; and A is -(CH₂)₂-, (CH₂)₃- ­or -CH=CH-; processes for their preparation, pharmaceutical compositions containing them and their use in therapy as inhibitors of gastric acid secretion.

  C₁₋₄烷硫基、C₁₋₄烷酰基、氨基、R⁵至 R⁹相同或不同且各自为氢、C₁₋₆alkyl、C₁₋₆alkoxy、C₁₋₆烷硫基、卤素、氰基、氨基、羟基、氨基甲酰基、羧基、C₁₋₆烷酰基、三氟甲基或硝基，R¹⁰除其他外为氢、C₁₋₆烷基、C₁₋₆烷氧基、卤素、羟基、-CH₂OH、C₁₋₆烷硫基、NH(CH₂)nOH（其中 n 为 0 至 4）或氨基；和 A 是-(CH₂)₂-、(CH₂)₃- 或-CH=CH-；它们的制备工艺、含有它们的药物组合物以及它们作为胃酸分泌抑制剂在治疗中的用途。
• Reversible inhibitors of the gastric (H+/K+)-ATPase. 2. 1-Arylpyrrolo[3,2-c]quinolines: effect of the 4-substituent
  作者：Colin A. Leach、Thomas H. Brown、Robert J. Ife、David J. Keeling、Shiona M. Laing、Michael E. Parsons、Carolyn A. Price、Kenneth J. Wiggall

  DOI：10.1021/jm00088a021

  日期：1992.5

  Further work on compounds 1 has identified the 4-position as a site where substantial modifications are tolerated, leading to analogues which are more potent and less toxic than those described previously. The best compound in the series is 13a (SK&F 96356), which is a potent inhibitor of gastric acid secretion in both the pentagastrin-stimulated rat and the histamine-stimulated dog. This compound shows reversible, K+-competitive binding to the enzyme. Because of its fluorescent properties, it is also proving useful in vitro as a probe of the structure and function of the (H+/K+)-ATPase.
• US5051508A
  申请人：——

  公开号：US5051508A

  公开（公告）日：1991-09-24
• 417. The synthesis of dictamnine and γ-fagarine
  作者：M. F. Grundon、N. J. McCorkindale

  DOI：10.1039/jr9570002177

  日期：——